Log In
BCIQ
Print this Print this
 

bimekizumab (UCB4940)

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionHumanized IgG1 mAb targeting IL-17A and IL-17F
Molecular Target Interleukin-17A (IL-17A) ; Interleukin-17F (IL-17F)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today